Other languages Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
4.64 ^USD	-7.57%		-7.57%	-14.39%

Jun. 06	Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial	MT
Jun. 06	Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial	Jun. 06
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data	Jun. 06
Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024	Jun. 06
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Sagimet Biosciences Names Thierry Chauche CFO	May. 06
Sagimet Biosciences Inc. Announces Executive Changes	May. 06
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	Mar. 27
Sagimet Biosciences Inc. Announces Management Changes	Mar. 25
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Top Premarket Decliners	Jan. 26
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell	Jan. 26
Sagimet Biosciences Launches Public Offering of Series A Common Shares	Jan. 24
Sector Update: Health Care Stocks Advance Late Afternoon	Jan. 22
Sector Update: Health Care Stocks Higher in Afternoon Trading	Jan. 22
Top Midday Gainers	Jan. 22
Sagimet Shares Climb After Positive Results From Study of NASH Treatment Denifanstat	Jan. 22
Sagimet's shares hit new high as fatty liver disease drug shows promise in study	Jan. 22
Sagimet's fatty liver disease drug shows promise in trial	Jan. 22
Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash	Jan. 22
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	Nov. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Other languages

Filters